Prokidney reports third quarter 2022 financial results and recent corporate highlights

Winston-salem, n.c., nov. 14, 2022 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today announced financial results for the third quarter ended september 30, 2022, and provided an update on recent corporate developments.

PROK Ratings Summary

PROK Quant Ranking